Valuation : ProPhase Labs, Inc.

Market Cap 4L 3L 3L 3L 5L 3.72Cr 5L 37.1L 14.5L 1.88Cr 14.64L 14.32L 6.21Cr P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 89.18L 76.55L 71.67L 65.63L 1.24Cr 85Cr 1.24Cr 8.49Cr 3.32Cr 43Cr 3.35Cr 3.28Cr 142.07Cr EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
92.7%
Yield 2024 *
-
Yield 2025 -

Last Transcript : ProPhase Labs, Inc.

1 day-7.60%
1 week-14.82%
Current month-44.69%
1 month-62.44%
3 months-76.90%
6 months-84.60%
Current year-94.84%
1 week 0.02
Extreme 0.0211
0.03
1 month 0.02
Extreme 0.0211
0.06
Current year 0.02
Extreme 0.0211
0.47
1 year 0.02
Extreme 0.0211
6.66
3 years 0.02
Extreme 0.0211
74.8
5 years 0.02
Extreme 0.0211
152.5
10 years 0.02
Extreme 0.0211
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25 Free

Chief Executive Officer

5,00,000 1.2036%
17/02/25 Free

Chief Operating Officer

5,00,000 1.6737%
14/02/25 Free

Director

1,00,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-7.60%-14.82%-99.30%-99.95% 4L
+0.15%+4.51%+108.23%+511.59% 4.88TCr
+1.36%+2.65%+22.32%+60.96% 2.72TCr
+0.20%-14.69%-15.69%-37.60% 710.41Cr
-1.52%-2.17%+5.74%+137.42% 601.8Cr
-0.05%+2.61%+17.06%+77.10% 339.33Cr
-0.65%+9.57%-29.99%+2,018.27% 269.25Cr
+10.07%+15.85%+170.48%+38.67% 223.16Cr
+0.37%+2.52%+32.44%+24.93% 196.59Cr
-1.45%+1.24%-7.80%-51.91% 194.3Cr
Average +0.08%+0.52%+20.35%+267.95% 1.01TCr
Weighted average by Cap. +0.52%+2.11%+61.33%+324.66%

Financials

2024 2025
Net sales 67.7L 58.11L 54.41L 49.82L 93.85L 65Cr 94.12L 6.44Cr 2.52Cr 33Cr 2.54Cr 2.49Cr 107.85Cr 43.45L 37.3L 34.92L 31.97L 60.23L 41Cr 60.4L 4.13Cr 1.62Cr 21Cr 1.63Cr 1.6Cr 69Cr
Net income -5.34Cr -4.58Cr -4.29Cr -3.93Cr -7.4Cr -509.67Cr -7.42Cr -51Cr -20Cr -256.87Cr -20Cr -20Cr -850.13Cr -1.47Cr -1.27Cr -1.18Cr -1.08Cr -2.04Cr -140.81Cr -2.05Cr -14Cr -5.48Cr -71Cr -5.54Cr -5.42Cr -234.87Cr
Net Debt 2.39Cr 2.05Cr 1.92Cr 1.76Cr 3.31Cr 228.22Cr 3.32Cr 23Cr 8.89Cr 115.02Cr 8.97Cr 8.78Cr 380.67Cr 85.28L 73.2L 68.54L 62.76L 1.18Cr 81Cr 1.19Cr 8.12Cr 3.17Cr 41Cr 3.2Cr 3.13Cr 135.86Cr
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
27/26/27 $0.0231 -7.60% 39,248
26/26/26 $0.0250 -7.06% 2,79,618
25/26/25 $0.0269 +8.91% 2,11,192
24/26/24 $0.0247 0.00% 46,311
21/26/21 $0.0247 -8.92% 1,37,377

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock